IVERIC bio, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2017-11-08: Form 8-K; Period of report 2017-11-08; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2017-11-07: Form 8-K; Period of report 2017-11-01; Description 1.01 Entry into a Material Definitive Agreement; Details 1.01.
- 2017-10-27: Form 8-K; Period of report 2017-10-23; Description 1.02 Termination of a Material Definitive Agreement; Details 1.02.
- 2017-08-14: Form 8-K; Period of report 2017-08-14; Description 8.01 Other Events; Details 8.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2017-11-08 | 8-K | 2017-11-08 | 2.02 Results of Operations and Financial Condition | 2.02 On November 8, 2017, Ophthotech Corporation announced its financial results for the quarter ended September 30, 2017. | item202x11082017.htm |
| 2017-11-07 | 8-K | 2017-11-01 | 1.01 Entry into a Material Definitive Agreement | 1.01 On November, 1 2017, Ophthotech Corporation (the “Company”) entered into a fifth amendment of lease (the “Fifth Lease Amendment”) with One Penn Plaza LLC, as landlord, amending, effective as of October 1, 2017, the Lease Agreement, dated as of September 30, 2007, between the Company and One Penn Plaza LLC, as previously supplemented and amended (as so supplemented and amended, the “Lease”). | opht-item_1x01x8kxvnoxleas.htm |
| 2017-10-27 | 8-K | 2017-10-23 | 1.02 Termination of a Material Definitive Agreement | 1.02 On October 24, 2017, Ophthotech Corporation (“Ophthotech”) received from Novartis Pharma AG (“Novartis” and, together with Ophthotech, the “LCA Parties”) a termination notice dated October 23, 2017 terminating with immediate effect the Licensing and Commercialization Agreement between Ophthotech and Novartis dated May 19, 2014 (the “LCA”). | opht-item_1x02x8kxnovartis.htm |
| 2017-08-14 | 8-K | 2017-08-14 | 8.01 Other Events | 8.01 On August 14, 2017, Ophthotech Corporation issued a press release announcing the results from its third Phase 3 clinical trial of Fovista® in wet age related macular degeneration. | item_801x901x08142017.htm |
| 2017-07-26 | 8-K/A | 2017-07-26 | 7.01 Regulation FD Disclosure | 7.01 On July 26, 2017, Ophthotech Corporation posted an updated investor presentation to its website at http://investors.ophthotech.com/events.cfm. | item701amendment107262017.htm |
| 2017-07-26 | 8-K | 2017-07-26 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure | 2.02 On July 26, 2017, Ophthotech Corporation announced its financial results for the quarter ended June 30, 2017. 7.01 On July 26, 2017, Ophthotech Corporation issued a press release announcing updates to its business plan as part of its ongoing strategic review. | item2_02x7x01x07262017.htm |
| 2017-07-10 | 8-K | 2017-07-03 | 1.01 Entry into a Material Definitive Agreement | 1.01 On July 3, 2017, Ophthotech Corporation (“Ophthotech”) and Novartis Pharma AG (“Novartis” and, collectively with Ophthotech, the “Parties”) entered into a letter agreement with respect to the Licensing and Commercialization Agreement by and between the Parties dated May 19, 2014 (the “LCA”). | opht-item_1x01x8kxnovartis.htm |
| 2017-05-22 | 8-K | 2017-05-17 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 Ophthotech held its Annual Meeting of Stockholders on May 19, 2017. | opht-item_5x07x8xkx2017xan.htm |
| 2017-05-03 | 8-K | 2017-05-03 | 2.02 Results of Operations and Financial Condition | 2.02 On May 3, 2017, Ophthotech Corporation announced its financial results for the quarter ended March 31, 2017. | item2_02x05032017.htm |
| 2017-04-24 | 8-K | 2017-04-24 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On April 24, 2017, Ophthotech Corporation (the “Company” or “Ophthotech”) entered into a letter agreement (the “Guyer Letter Agreement”) with David R. Guyer, M.D., the Company’s Chief Executive Officer (“CEO”), providing for Dr. Guyer’s transition to Executive Chairman of the Board of Directors (the “Board”) of the Company. | a17-11712_18k.htm |
| 2017-03-31 | 8-K/A | 2016-06-02 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 As reported in the Original Filing, at the Annual Meeting, in accordance with the recommendation of the Board of Directors, the Company’s stockholders recommended, by advisory vote, a one-year frequency of future advisory votes on the compensation of the Company’s named executive officers. | opht-8ka507.htm |
| 2017-02-28 | 8-K | 2017-02-28 | 2.02 Results of Operations and Financial Condition | 2.02 On February 28, 2017, Ophthotech Corporation announced its financial results for the quarter and year ended December 31, 2016. | item2028-k.htm |
| 2017-02-24 | 8-K | 2017-02-20 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On February 20, 2017, Ian Smith notified Ophthotech Corporation (the “Company”) of his request not to be nominated for re-election to the Board of Directors (the “Board”) of the Company when his current term expires at the Company’s 2017 annual meeting of stockholders. | item5028-kfebruary2017.htm |
| 2017-02-01 | 8-K | 2017-01-26 | 1.02 Termination of a Material Definitive Agreement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 1.02 On January 26, 2017, Ophthotech Corporation (the “Company”) issued a notice of termination under the Lease Agreement, dated as of September 30, 2007, between the Company and One Penn Plaza LLC, as previously supplemented and amended (as so supplemented and amended, the “Lease”) for office space at One Penn Plaza in New York, New York. 5.02 As part of implementing the Company’s updated business plan, on January 30, 2017, Glenn P. Sblendorio, age 60, was appointed as President of the Company, effective immediately. | a17-3584_18k.htm |
| 2017-01-17 | 8-K | 2017-01-11 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On January 12, 2017, Ophthotech Corporation (the “Company”) and Samir C. Patel, M.D. entered into a Separation and Release of Claims Agreement (the “Separation Agreement”), pursuant to which Dr. Patel resigned from his employment with the Company, as an officer of the Company and as a member of the Company’s Board of Directors, effective as of January 13, 2017. | a17-2540_18k.htm |
| 2017-01-17 | 8-K/A | 2017-01-16 | 2.05 Costs Associated with Exit or Disposal Activities | 2.05 On December 16, 2016, the Company announced that it had determined to implement a reduction in personnel to focus on an updated business plan. | a17-2540_28ka.htm |
| 2017-01-06 | 8-K | 2017-01-05 | 1.02 Termination of a Material Definitive Agreement | 1.02 On January 5, 2017, Ophthotech Corporation (“Ophthotech”) provided written notice to Ajinimoto Althea, Inc. (“Althea”), terminating the Capacity Reservation Agreement (the “CRA”) entered into as of October 31, 2016 by and between Ophthotech and Althea. | opht-8kaltheatermination.htm |